BCL2A1 may control CD4+ cell activation and differentiation into pro-inflammatory TH17 cells, and BCL2A1 is a potential target for controlling autoimmune/inflammatory diseases.[29] MMP-3 is a significant contributor to joint conditions such as TMJ disease and rheumatism. This evidence concerns the gene CD4 and rheumatic disorder.